鶹ýӰ

Automated Insulin System OK'd; Zepbound Gains in Popularity; Male Menopause Cures?

— News and commentary from the endocrinology world

by Kristen Monaco, Senior Staff Writer, MedPage Today

MedpageToday
Endo Break over a computer rendering of a man with illustrated body organs.

The FDA cleared the powered by Tidepool for patients 6 and older with type 1 diabetes, said maker Sequel Med Tech. It's the first drug delivery system to directly measure the volume and flow of insulin delivered with every micro-dose.

After 1 year, diabetic and nondiabetic (Mounjaro, Zepbound) or injectable semaglutide (Ozempic, Wegovy) had more median weight loss than those on other GLP-1 agonists, including liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), or oral semaglutide (Rybelsus). (Epic Research)

For the first time since the drugs launched, in new prescriptions for weight loss. (Reuters)

Bayer plans to submit for the treatment of moderate to severe vasomotor symptoms associated with menopause to the FDA after the latest installment of the OASIS clinical program demonstrated long-term safety.

Though the weight-loss formulation of semaglutide gained a heart health indication earlier this month, some insurers are . (CNBC)

Compared with placebo, tirzepatide consistently and significantly -- overweight, class I, class II, and class III obesity -- according to a study slated to be presented at the European Congress on Obesity in May.

Metabolic surgery for was associated with lower blood pressure, reduced blood lipids, and a 35% reduction in cardiovascular disease at 10 years, among other benefits. (Journal of the Endocrine Society)

The Endocrine Society praised Congress for approving a for the first time since 2004.

in adults with overweight or obesity was better at improving a slew of cardiometabolic outcomes compared with a regular diet or continuous energy restriction, according to a meta-analysis of randomized trials. (eClinicalMedicine)

Increased rates of overweight and obesity among 3- and 4-year-old kids after spiking early on in the pandemic. (JAMA Pediatrics)

Despite FDA rules on off-label marketing, some telehealth companies are still promising cures for . (CBS News)

Eli Lilly said it's to deliver its weight-loss injection drug tirzepatide among others. (Reuters)

  • author['full_name']

    Kristen Monaco is a senior staff writer, focusing on endocrinology, psychiatry, and nephrology news. Based out of the New York City office, she’s worked at the company since 2015.